Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | TP53 | P04637 | 2/20 | 0.84 |
| ▸ | MAPT | P10636 | 1/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.84 |
| ▸ | ACHE | P22303 | 5/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.53 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.53 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 2/20 | 0.52 |
| ▸ | HINT1 | P49773 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120550 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL3478703 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL1120556 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL278443 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL1120553 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13924747 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13296259 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL3427712 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL6363586 | 0.95 | LMNA (0.76) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL17198377 | 0.93 | ALDH1A1 (0.73) | LMNAALDH1A1TP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD SCIENCE, INC. | 2012-08-02 | — | — | US | disclosed |
| US-8183226-B2 | Myocardial perfusion imaging method | GILEAD SCIENCES, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8133879-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110144320-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | GILEAD PALO ALTO, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | GILEAD PALO ALTO, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD PALO ALTO, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100160620-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | GILEAD PALO ALTO, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100081810-A1 | C-Pyrazole A2A Receptor Agonists | CV THERAPEUTICS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081810-A1 | C-Pyrazole A2A Receptor Agonists | CV THERAPEUTICS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-7683037-B2 | A2A receptor agonist; regadenoson (CVT-3146); produces coronary vasodilation without significant peripheral vasodilation; | GILEAD PALO ALTO, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7655637-B2 | N-pyrazole A2A receptor agonists | GILEAD PALO ALTO, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655637-B2 | N-pyrazole A2A receptor agonists | GILEAD PALO ALTO, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7553823-B2 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070203090-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20060052332-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2006-03-09 | — | — | US | disclosed |
| US-20040038928-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2004-02-26 | — | — | US | disclosed |
| US-6642210-B1 | Administering compound to mammal by intravenous bolus injection to stress heart and induce coronary steal situation, stimulating coronary vasodilation, in order to image heart | CV THERAPEUTICS, INC. | 2003-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038928-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, ADORA1 | LMNA 3308/4885ALDH1A1 1118/4885TP53 4170/4885 |
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | LMNA 1298/4885ALDH1A1 1336/4885TP53 2068/4885 |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | ADORA2A, ADORA3, ADORA2B | LMNA 2390/4885ALDH1A1 1258/4885TP53 4038/4885 |
| US-20060052332-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | LMNA 3247/4885ALDH1A1 1264/4885TP53 4204/4885 |
| US-20110144320-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | ADORA2A, ADORA3, TBXA2R | LMNA 3247/4885ALDH1A1 1264/4885TP53 4204/4885 |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | ADORA2A, ADORA3, ADORA1 | LMNA 1087/4885ALDH1A1 1130/4885TP53 4421/4885 |
| US-20100160620-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | ADORA2A, ADORA3, TBXA2R | LMNA 3247/4885ALDH1A1 1264/4885TP53 4204/4885 |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | ADORA2A, ADORA3, ADRB3 | LMNA 1171/4885ALDH1A1 2120/4885TP53 4642/4885 |
| US-20100081810-A1 | C-Pyrazole A2A Receptor Agonists | ADORA2A, ADORA3, TBXA2R | LMNA 2553/4885ALDH1A1 1002/4885TP53 4377/4885 |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | LMNA 1298/4885ALDH1A1 1336/4885TP53 2068/4885 |
| US-20070203090-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | LMNA 3247/4885ALDH1A1 1264/4885TP53 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.